Patents Assigned to Bioscience, Inc.
  • Patent number: 12091463
    Abstract: The present invention relates, in part, to agents that bind Clec9A and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: September 17, 2024
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier, Lennart Zabeau, Erik Depla
  • Patent number: 12091438
    Abstract: The present application relates to anti-mesothelin constructs (such as antimesothelin antibodies, cytokine fusion proteins that comprise the anti-mesothelin constructs), methods of preparing the anti-mesothelin constructs and methods of using the constructs (e.g., methods of treating a disease or condition). The present application also relates to a combination therapy for treating cancer that comprises administering anti-mesothelin agent and a cytokine (such as IL-21 or IL-15). Combination therapy may further comprises administration of an anti-Her2 agent.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: September 17, 2024
    Assignee: Anwita Biosciences, Inc.
    Inventors: Ziyang Zhong, Fan Ye, Matthew Siegel, Jianing Huang
  • Publication number: 20240299409
    Abstract: Provided are methods of treating a cerebral cavernous malformation (CCM) and methods of treating cerebral aneurysm in a mammal with certain rho kinase inhibitors.
    Type: Application
    Filed: February 20, 2024
    Publication date: September 12, 2024
    Applicant: BioAxone BioSciences, Inc.
    Inventors: Kenneth M. ROSEN, Steven Wayne RIESINGER, Lisa MCKERRACHER, Lisa BOND MORITZ
  • Publication number: 20240301379
    Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure may leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
    Type: Application
    Filed: May 29, 2024
    Publication date: September 12, 2024
    Applicant: Mammoth Biosciences, Inc.
    Inventors: Lucas Benjamin HARRINGTON, David PAEZ-ESPINO, Benjamin Julius RAUCH, Stepan TYMOSHENKO
  • Publication number: 20240299585
    Abstract: Disclosed are engineered meganucleases that bind and cleave a recognition sequence within a hydroxyacid oxidase 1 (HAO1) gene. The present invention also encompasses methods of using such engineered meganucleases to make genetically-modified cells. Further, the invention encompasses pharmaceutical compositions comprising engineered meganuclease proteins, or nucleic acids encoding engineered meganucleases of the invention, and the use of such compositions for treatment of primary hyperoxaluria type I (PH1).
    Type: Application
    Filed: January 7, 2022
    Publication date: September 12, 2024
    Applicant: Precision BioSciences, Inc.
    Inventors: James Jefferson Smith, Janel Lape, John Morris
  • Patent number: 12084497
    Abstract: The present invention relates, in part, to agents that bind SIRP1? and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the SIRP1? targeting moiety and their use in the treatment of various diseases.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 10, 2024
    Assignees: Orionis Biosciences, Inc., Orionis Biosciences BV
    Inventors: Nikolai Kley, Jan Tavernier
  • Patent number: 12084713
    Abstract: Provided herein are compositions and methods for the multiplexed profiling of RNA and DNA modifications across transcriptomes and genomes, respectively. The methods combine molecular recognition of non-canonical features (e.g., base modifications, backbone modifications, lesions, and/or structural elements) of a target nucleic acid with a step of writing the information from this recognition event into the neighboring genetic sequence of the target nucleic acid using a barcode. The resultant barcoded nucleic acids are then converted into sequencing libraries and read by DNA/RNA sequencing methods. This step reveals the sequence of the barcode, which is correlated with the non-canonical feature in the target nucleic acid(s). The high throughput profiling methods described herein allow for localization of one or more modifications in a target nucleic acid. The methods also allow for identification of the nature and location of several or all DNA/RNA modifications in parallel.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: September 10, 2024
    Assignee: Alida Biosciences Inc.
    Inventors: Gudrun Stengel, Byron Purse, Yu-Hsien Hwang-Fu, Jerome Santos
  • Patent number: 12084502
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: September 10, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Patent number: 12082878
    Abstract: A sub-microsecond pulsed electric field generator is disclosed. The field generator includes a controller, which generates a power supply control signal and generates a pulse generator control signal, and a power supply, which receives the power supply control signal and generates one or more power voltages based on the received power supply control signal. The field generator also includes a pulse generator which receives the power voltages and the pulse generator control signal, and generates one or more pulses based on the power voltages and based on the pulse generator control signal. In some embodiments, the controller receives feedback signals representing a value of a characteristic of or a result of the pulses and generates at least one of the power supply control signal and the pulse generator control signal based on the received feedback signals.
    Type: Grant
    Filed: May 22, 2023
    Date of Patent: September 10, 2024
    Assignee: Pulse Biosciences, Inc.
    Inventors: Shu Xiao, Brian G. Athos, Mark P. Kreis, David J. Danitz, Darrin R. Uecker
  • Patent number: 12083079
    Abstract: Provided are processes for the prevention or treatment of viral infection in a subject. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the nose or interior of the nose or portion thereof, the ability of viruses to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: September 10, 2024
    Assignee: Harbins Ruhr Bioscience, Inc.
    Inventors: Erich Gulbins, Karl Sebastian Lang, Judith Bezgovsek
  • Patent number: 12083227
    Abstract: The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: September 10, 2024
    Assignees: AbbVie Inc., Neurocrine Biosciences, Inc.
    Inventors: Yihong Qiu, Yuchuan Gong, Alexander Ruggles, Jared A. Baird, Hui Zu, Gregory A. McClelland, Anna V. Stepanenko
  • Patent number: 12084672
    Abstract: A genetically engineered land plant that expresses a protein that has homology to a plant invertase inhibitor and/or a pectin methylesterase inhibitor and that increases seed yield with increased expression (“an ISY protein”) is disclosed. The plant comprises a modified gene for the ISY protein. The ISY protein comprises one or more of an ISY protein of Camelina sativa comprising SEQ ID NO: 2 or a fragment, Camelina sativa homolog, or ortholog thereof. The modified gene comprises a promoter and a nucleic acid sequence encoding the ISY protein. The promoter is non-cognate with respect to the nucleic acid sequence encoding the ISY protein. The modified gene is configured such that transcription of the nucleic acid sequence is initiated from the promoter and results in expression of the ISY protein. A genetically engineered land plant that expresses an RNA that increases seed yield with increased expression also is disclosed.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: September 10, 2024
    Assignee: Yield10 Bioscience, Inc.
    Inventors: Jihong Tang, Meghna Malik, Nirmala Sharma, Claire Burkitt, Yuanyuan Ji, Madana M. R. Ambavaram, Kieran Ryan, Oliver P. Peoples, Kristi D. Snell, Frank Anthony Skraly, Venkatesh Bollina
  • Publication number: 20240294861
    Abstract: Aspects relate to an automated cell culture incubator and to methods for using such an incubator. In one aspect, the cell culture incubator includes an incubator cabinet having a transfer chamber and an internal chamber that are arranged to form an airlock configuration. In some embodiments, objects placed into the incubator cabinet are sterilized using ozone produced by an ozone generator. The incubator may include one or more transfer devices that move objects between the transfer chamber and the internal chamber.
    Type: Application
    Filed: January 30, 2024
    Publication date: September 5, 2024
    Applicant: Thrive Bioscience, Inc.
    Inventor: Alan Blanchard
  • Patent number: 12076366
    Abstract: The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
    Type: Grant
    Filed: July 3, 2020
    Date of Patent: September 3, 2024
    Assignee: Extend Biosciences, Inc.
    Inventors: Tarik Soliman, Laura M. Hales, Daniel B. Hall, Christopher So, Howard P. Sard, Vishnumurthy Hegde
  • Patent number: 12077775
    Abstract: Provided herein are compositions, systems, and methods comprising effector proteins and uses thereof. These effector proteins are shown to be active with guide RNAs and may be characterized as CRISPR-associated (Cas) proteins. Various compositions, systems, and methods of the present disclosure leverage the activities of these effector proteins for the modification, detection, and engineering of nucleic acids.
    Type: Grant
    Filed: June 12, 2023
    Date of Patent: September 3, 2024
    Assignee: Mammoth Biosciences, Inc.
    Inventors: Aaron Deloughery, Matan Drory Retwitzer, Lucas Benjamin Harrington, Wiputra Jaya Hartono, Alexander Richard Neckelmann, David Paez-Espino, Benjamin Julius Rauch, Clarissa Oriel Rhines, Stepan Tymoshenko, Fnu Yunanda, William Douglass Wright
  • Patent number: 12076072
    Abstract: A pulse generator discharge circuit is disclosed. The circuit includes one or more discharge stages, each discharge stage including a plurality of control input terminals. The circuit also includes first and second discharge terminals, and a plurality of serially connected switches electrically connected between the first and second discharge terminals, where a conductive state of each of the switches is controlled by a control signal. The circuit also includes a plurality of inductive elements configured to generate the control signals for the serially connected switches, where each inductive element is configured to generate a control signal for one of the serially connected switches in response to one or more input signals at one or more of the control input terminals, and where each of the serially connected switches is configured to receive a control signal from a respective one of the inductive elements.
    Type: Grant
    Filed: June 21, 2023
    Date of Patent: September 3, 2024
    Assignee: Pulse Biosciences, Inc.
    Inventors: Brian G. Athos, Darrin R. Uecker, Shu Xiao
  • Patent number: 12077605
    Abstract: Described herein are Mpro cysteine protease inhibitors and methods of utilizing such inhibitors in the treatment of diseases, disorders, or conditions. Also described herein are pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: September 3, 2024
    Assignee: Anixa Biosciences, Inc.
    Inventors: Wolfgang Richter, Muhammad Abbas, Lutz Weber, Amit Kumar
  • Patent number: 12079960
    Abstract: An exemplary system, method and computer-accessible medium for harmonizing neuromelanin (NM) data using combat directly on a NM database or using combat generated coefficients to harmonize future data can include, for example, receiving imaging information of a brain of the patient(s), from one MRI scanner, receiving imaging information of a brain of the patient(s), from a second MRI scanner and using combat to harmonize the data between scanners against a reference dataset. The Neuromelanin (NM) concentration of the patient(s) can then be determined based on the harmonized data. The NM concentration can be determined using a voxel-wise analysis procedure. The voxel-wise analysis procedure can be used to determine a topographical pattern(s) within a substantia nigra (SN) of the brain of the patient(s).
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 3, 2024
    Assignees: Terran Biosciences Inc., The Trustees of Columbia University in the City of New York, The Research Foundation for Mental Hygiene, Inc.
    Inventors: Samuel Clark, Kenneth Wengler, Guillermo Horga Hernandez
  • Patent number: 12076411
    Abstract: The present disclosure provides anti-HER2 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: September 3, 2024
    Assignee: Redwood Bioscience, Inc.
    Inventors: David Rabuka, Aaron Edward Albers, Robyn M. Barfield, Gregory W. deHart, Penelope M. Drake, Romas Alvydas Kudirka, Albert W. Garofalo, Jesse M. McFarland
  • Patent number: D1042881
    Type: Grant
    Filed: May 4, 2022
    Date of Patent: September 17, 2024
    Assignee: Harvard Bioscience Inc.
    Inventor: Tyler Robert Eisner